Advancing Drug Development with a Hands-On Approach

Abzena are delighted and thankful to have been awarded ‘Top Contract Manufacturing Organization 2025’ by Life Sciences Review.

The award is in recognition of Abzena’s stellar reputation and trust among customers and industry peers, evident in the numerous nominations received from subscribers of Life Sciences Review.

Take a look at the latest article in full at Life Sciences Review featuring our CEO, Matt Stober, as he shares his thoughts on advancing drug development for our customers with a hands-on approach. You can also read a snippet of the article below.

Abzena’s customer base is comprised of small and mid-sized biotech companies and large multi-national pharmaceutical firms. Leveraging the deep scientific expertise of its 450+ professionals, including 75 PhDs their global scientific teams work closely with customers to align projects with timelines and product performance goals to ensure a successful outcome.

“One thing that differentiates us as a drug development partner is that we get more involved with companies that may have a single target or a few programs in their pipeline,” says Matt Stober, CEO. “We understand how important these programs are to these companies, and we stay highly engaged with their leadership teams to ensure development moves along at the necessary pace for them to keep moving forward.”

The impact of this hands-on collaboration is evident in Abzena’s success stories. In one instance, a biotech startup developing an antibody-oligo conjugate (AOC) sought Abzena’s support during its early stages. With only three employees and an initial funding of $20 million, the client needed scientific and technical expertise to bring the product to market. The company’s team helped develop the processes, expand the clinical pipeline and generate necessary data to secure additional funding. Now a publicly traded organization, the biotech startup is valued at over $3 billion, with two clinical assets advancing to phase three.

In another instance, Abzena assisted a RDC company that faced early-stage product development and supply chain challenges. The company worked closely with the customer’s supply chain partners to refine manufacturing processes and meet stringent regulatory requirements. This enabled a seamless transition from early clinical trials to phase three, supported by strong data and a refined strategy for bringing the drug to market.

Abzena excels at integrating scientific expertise with a collaborative mindset, ensuring meaningful impact beyond individual projects. Instead of leveraging cookie-cutter solutions, it invests in understanding customer’s goals, challenges, and ambitions.

Read the full article here

Interested in finding out more about how we can help move your idea forward. Contact our experts today to learn more.